These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19560809)

  • 21. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 22. Adalimumab in juvenile rheumatoid arthritis.
    Taddio A; Marchetti F
    N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
    [No Abstract]   [Full Text] [Related]  

  • 23. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?
    O'Dell JR
    N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958
    [No Abstract]   [Full Text] [Related]  

  • 24. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
    Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF;
    Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349
    [No Abstract]   [Full Text] [Related]  

  • 25. COBRA combination therapy in daily practice--getting back to the future.
    Boers M
    Rheumatology (Oxford); 2008 Jan; 47(1):1-2. PubMed ID: 18077485
    [No Abstract]   [Full Text] [Related]  

  • 26. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Thompson AE; Rieder SW; Pope JE
    Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach.
    Devine EB; Alfonso-Cristancho R; Sullivan SD
    Pharmacotherapy; 2011 Jan; 31(1):39-51. PubMed ID: 21182357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trial of etanercept and methotrexate with radiographic and patient outcomes two-year clinical and radiographic results: Comment on the article by van der Heijde et al.
    Yazici Y; Yazici H
    Arthritis Rheum; 2006 Sep; 54(9):3061-2. PubMed ID: 16948140
    [No Abstract]   [Full Text] [Related]  

  • 30. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
    Papagoras C; Voulgari PV; Drosos AA
    Autoimmun Rev; 2010 Jun; 9(8):574-82. PubMed ID: 20433955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
    Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
    Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
    Bukhari M; Abernethy R; Deighton C; Ding T; Hyrich K; Lunt M; Luqmani R; Kiely P; Bosworth A; Ledingham J; Ostör A; Gadsby K; McKenna F; Finney D; Dixey J;
    Rheumatology (Oxford); 2011 Dec; 50(12):2311-3. PubMed ID: 21546351
    [No Abstract]   [Full Text] [Related]  

  • 34. New drugs for rheumatoid arthritis.
    Kalil AC
    N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15609422
    [No Abstract]   [Full Text] [Related]  

  • 35. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
    Bendtzen K
    Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
    [No Abstract]   [Full Text] [Related]  

  • 36. [Combination therapy for rheumatoid arthritis].
    Sibilia J
    Ann Med Interne (Paris); 2002 Feb; 153(1):41-52. PubMed ID: 11994689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply to letter by Yazici and Yazici commenting on the two-year report on the trial of etanercept and methotrexate with radiographic and patient outcomes.
    van der Heijde D; Klareskog L
    Arthritis Rheum; 2007 Mar; 56(3):1031-2. PubMed ID: 17328083
    [No Abstract]   [Full Text] [Related]  

  • 38. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients.
    Köller MD; Aletaha D; Funovits J; Pangan A; Baker D; Smolen JS
    Rheumatology (Oxford); 2009 Dec; 48(12):1575-80. PubMed ID: 19812228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Infliximab for therapy of rheumatoid arthritis].
    Amano K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():517-20. PubMed ID: 15799410
    [No Abstract]   [Full Text] [Related]  

  • 40. [Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].
    Imagama T; Taguchi T
    Nihon Rinsho; 2013 Jul; 71(7):1209-13. PubMed ID: 23961668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.